EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

6. Does adding vitamin B12 or changing the dose avoid the copying restrictions?

Dose Diligence research deskSection 01 · Page 6 of 34Last updated 17 Nov 2026

Not automatically. FDA’s April 1, 2026 clarification specifically explains that a semaglutide–B12 combination may still be considered essentially a copy under the circumstances it describes. (fda.gov)

Similarly, FDA’s 503A guidance addresses minor strength changes and easily substitutable strengths; a cosmetic difference is not a general exemption. (fda.gov)

Treat these supplier statements as requests for evidence, not conclusions:

  • The formula is personalized.
  • The dose is different from the branded pen.
  • B12 makes it a different medicine.
  • Every patient receives an individual prescription.

For each, request the exact formulation, applicable legal test and independent prescriber documentation. An ingredient addition also warrants clinical review of its purpose—not just a commercial explanation of why it enables continued selling.

Decision rule: unresolved copying questions remain a procurement gate. They should not receive a low risk score that can be offset by a large discount.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
Section sources →